As such, inhibition of TKs has been explored as a potential medium for treating cancer: TKIs such as nilotinib, imatinib, and dasatinib, etc. have been utilized to treat various cancers by blocking TK-mediated cellular proliferation, primarily due to their ability to induce autophagy-dependent apoptosis of cancer cells (Nam et al., 2005; Yu et al., 2013; Iqbal and Iqbal, 2014). Here, CDC42 is linked to cancer.